Brisbane, CA, United States of America

Kenneth James Shaw

USPTO Granted Patents = 4 


Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2010-2011

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Innovations of Kenneth James Shaw

Introduction

Kenneth James Shaw is a notable inventor based in Brisbane, CA (US). He has made significant contributions to the field of biotechnology, particularly in understanding the IGFR pathway. With a total of 4 patents, his work has implications for therapeutic targets in various disorders.

Latest Patents

Shaw's latest patents include groundbreaking research on the C20ORF23 gene, which is identified as a modulator of the IGFR pathway. This discovery highlights its potential as a therapeutic target for disorders associated with defective IGFR function. Additionally, he has worked on patents related to PDE genes, which are also recognized as modulators of the IGFR pathway. These patents provide methods for identifying agents that can modulate the activity of both C20ORF23 and PDE.

Career Highlights

Kenneth Shaw is currently associated with Exelixis, Inc., where he continues to advance his research. His work has been instrumental in paving the way for new therapeutic strategies in the treatment of diseases linked to IGFR dysfunction.

Collaborations

Some of his notable coworkers include Lori Friedman and Helen Louise Francis-Lang, who have collaborated with him on various projects.

Conclusion

Kenneth James Shaw's innovative work in the field of biotechnology, particularly regarding the IGFR pathway, showcases his commitment to advancing medical science. His contributions are paving the way for future therapeutic developments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…